Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Lesogaberan
Другие языки:

Lesogaberan

Подписчиков: 0, рейтинг: 0
Lesogaberan
Lesogaberan.svg
Lesogaberan ball-and-stick model.png
Names
Preferred IUPAC name
[(2R)-3-Amino-2-fluoropropyl]phosphinic acid
Other names
AZD-3355
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.133.162
PubChem CID
UNII
  • InChI=1S/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1 ☒N
    Key: LJNUIEQATDYXJH-GSVOUGTGSA-N ☒N
  • InChI=1/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1
    Key: LJNUIEQATDYXJH-GSVOUGTGBQ
  • O=[PH](O)C[C@H](F)CN
Properties
C3H9FNO2P
Molar mass 141.082 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABAB receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.


Новое сообщение